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From bedside to bench: regulation of host factors
in SARS-CoV-2 infection
Samantha Y. Q. Ong1, Ilya M. Flyamer2, Wendy A. Bickmore2 and Simon C. Biddie 1,2
Abstract
The zoonotic coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), which causes COVID-19
(coronavirus disease-2019), has resulted in a pandemic. This has led to an urgent need to understand the molecular
determinants of SARS-CoV-2 infection, factors associated with COVID-19 heterogeneity and severity, and therapeutic
options for these patients. In this review, we discuss the role of host factors in SARS-CoV-2 infection and describe
variations in host factor expression as mechanisms underlying the symptoms and severity of COVID-19. We focus on
two host factors, angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2),
implicated in SARS-CoV-2 infection. We also discuss genetic variants associated with COVID-19 severity revealed in
selected patients and based on genome-wide association studies (GWASs). Furthermore, we highlight important
advances in cell and chromatin biology, such as single-cell RNA and chromatin sequencing and chromosomal
conformation assays, as methods that may aid in the discovery of viral–host interactions in COVID-19. Understanding
how regulation of host factor genes varies in physiological and pathological states might explain the heterogeneity
observed in SARS-CoV-2 infection, help identify pathways for therapeutic development, and identify patients most
likely to progress to severe COVID-19.
Introduction
The emergence of the novel coronavirus (CoV) severe
acute respiratory syndrome (SARS) coronavirus 2 (SARS-
CoV-2) has resulted in a pandemic. In general, the het-
erogenous symptomatology following SARS-CoV-2
infection, which ranges from asymptomatic to severe
life-threatening COVID-19, suggests the involvement of
host factors. Epidemiological studies to date have impli-
cated several host factors in severe COVID-19, including
male sex, older age, cardiovascular disease, obesity, and
diabetes1,2. These host factors have behavioral, environ-
mental, and genetic contributions3.
Sequencing of the SARS-CoV-2 genome has enabled
comparative studies with other beta-coronaviruses to
identify pathogenic features. For example, the structural
similarity of the SARS-CoV-2 and SARS-CoV spike (S)
proteins has accelerated the identification of angiotensin-
converting enzyme 2 (ACE2) as a key host factor for viral
entry4. The endogenous role of ACE2 is to hydrolyse the
vasoconstrictor peptide angiotensin. Attachment of
SARS-CoV-2 to host cells is mediated by binding of the
viral S1 subunit receptor-binding domain to ACE2, per-
mitting entry and replication5. Following ACE2 engage-
ment, proteolytic cleavage of S2 by host proteases, such as
plasma membrane-associated type II transmembrane
serine protease (TMPRSS2), mediates membrane fusion
and cytosolic release of the viral RNA. TMPRSS2 is
essential for the establishment of airway infection by
SARS-CoV-2 and other zoonotic and human CoVs5.
In general, understanding host factor regulation
through chromatin structure and DNA-binding factor
analyses in various cell types and pathophysiological states
is crucial. In this review, we discuss the transcriptional
regulation of host factors associated with SARS-CoV-2
and severe COVID-19. We focus on key host factors for
SARS-CoV-2 infection, namely, ACE2 and TMPRSS2,
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and examine their expression in cell types linked to
symptoms. We also explore regulatory control and
context-dependent changes in host factor expression
associated with infection and risk phenotypes. Further-
more, we review genetic variants that might confer an
increased risk of severe COVID-19 and outline meth-
odologies to guide genotype-phenotype correlation for
functional validation of host factors.
ACE2 and TMPRSS2 tissue distribution and
correlation with clinical presentation
High-throughput sequencing of RNA (RNA-seq) has
shown ubiquitous expression of ACE2 and TMPRSS2.
ACE2 expression is particularly enriched in the lungs,
heart, kidneys, intestine, brain, skin, oral mucosa, and
endothelial cells6 (Fig. 1a). TMPRSS2 is mainly expres-
sed in the prostate, salivary glands, and luminal epithelia
of the gastrointestinal, urogenital and respiratory tracts7
(Fig. 1b). Patterns of ACE2 expression correlate with
susceptibility to infection with SARS-CoV8, leading to
the hypothesis of higher SARS-CoV-2 tropism for tis-
sues with higher ACE2 expression and consequent
symptomatology.
ACE2 and TMPRSS2 expression and pulmonary pathology
Mainly transmitted through droplets, aerosols, and
direct contact, the predominant targets of SARS-CoV-2
are the upper respiratory epithelium and lungs. COVID-
19 typically presents with constitutional respiratory
symptoms, with the majority of patients having pyrexia
and dry cough9. The central role of the lung in COVID-19
is supported by a significant rise in SARS-CoV-2 viral load
in these organs in more severe disease, which does not
occur in stool or serum10. In 10-20% of patients, the
disease progresses in severity with bilateral ground-glass
opacities on chest computed tomography11. In the first
wave of COVID-19, approximately 5–20% of patients
became critically ill, requiring invasive mechanical venti-
lation due to acute respiratory distress syndrome (ARDS)
with bilateral diffuse alveolar damage and cellular exu-
dates on postmortem analysis12.
Given their role in SARS-CoV-2 infection, expression of
the ACE2 and TMPRSS2 genes in the lung may contribute
to the observed pathology. Immunohistochemistry
demonstrates the highest expression of the ACE2 protein
within the sinonasal cavity and pulmonary alveoli, which
are presumptive sites of viral transmission and disease
development13. Single-cell RNA-seq (scRNA-seq) of
healthy adult lung tissue from eight donors showed that
<1% of cells in the lung parenchyma expressed ACE2
mRNA, 83% of which were surfactant-producing alveolar
type 2 (AT2) cells14. A low proportion of ACE2+ cells has
been observed in other scRNA-seq datasets, with pro-
portionally higher ACE2+ AT2 cells than other cell
types13,15. Consistent with immunohistochemical evi-
dence of ACE2 expression on apical surfaces13, this pro-
vides compelling evidence for that the virus targets AT2
cells. scRNA-seq studies have also found that a subset of
ACE2+ cells strongly coexpress TMPRSS2 and other viral
process-related genes, suggesting enhanced vulnerability
of AT2 cells to SARS-CoV-213,16. AT2 cells may thus
represent a potential viral reservoir for replication or
alternatively undergo viral-induced cell death to initiate
barrier damage and inflammation.
The proinflammatory state of COVID-19 may also
contribute to ACE2 expression through proinflammatory
transcription factor (TF) binding. scRNA-seq of the
human lung revealed that ACE2 expression is associated
with expression of interferon-stimulated genes (ISGs) and
components of the type I interferon (IFN) signaling
pathway, which is central to the immediate antiviral
response17. In primary human upper airway epithelial
cells, stimulation with IFN-γ and IFN-α2 leads to ACE2
upregulation, possibly through signal transducer and
activator of transcription-1 (STAT-1) binding sites in the
ACE2 promoter17. Similarly, human goblet secretory cells
of the nasal epithelia exhibit ACE2 upregulation in
response to influenza viruses, likely via an IFN pathway17.
IFN-induced ACE2 expression may confer susceptibility
to severe disease: local induction of IFN and ISG have
been observed in the bronchoalveolar lavage (BAL) of
critically ill patients18, and high circulating IFN levels have
been shown to persist in later stages of severe COVID-
1919. Nevertheless, IFN-induced expression has been
shown to represent a non-functional truncated ACE2
isoform, suggesting that conditions of high IFN levels are
unlikely to increase viral S-protein-mediated cellular entry
to promote infection20. Furthermore, the paucity of IFN
production and high viral loads observed in the incuba-
tion phase21,22 suggest a protective role for IFN in early
disease, which is currently being evaluated in clinical
trials23. The relationship between spatiotemporal kinetics
and tissue specificity of IFN responses and host factor
expression during SARS-COV-2 infection requires
further study.
Extrapulmonary involvement and host factor expression
Several extrapulmonary manifestations of COVID-19
have been observed, from benign symptoms involving the
eyes and gastrointestinal and nasal systems to severe
organ failure involving the neurological, cardiac, and renal
systems. Diarrhea occurs in approximately 5% of cases24,
while headache and anosmia have been described as
common early symptoms25. Regarding severe cases, acute
cardiac injury was seen in 12% of patients in a Chinese
cohort26. Severe acute kidney injury (AKI) requiring renal
replacement therapy is common among critically ill
patients, affecting 20-40% of those in the ICU1.
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Fig. 1 ACE2 and TMPRSS2 mRNA human tissue expression. Representation of RNA-seq-derived median protein-transcripts per million (pTPM)
levels of ACE2 (a) and TMPRSS2 (b) genes in 54 nondiseased tissue sites in females (left) and males (right). Organs not labeled include the brain, aorta,
coronary artery, heart, lungs, liver, esophagus, stomach, terminal ileum, colon (transverse, sigmoid), adrenal glands, kidney, and bladder. Data were
obtained from Genotype-Tissue Expression (GTEx) Portal V8107.
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The severity and multisystem involvement observed in a
subset of COVID-19 patients suggest a possible role for
viral interaction with extrapulmonary host factors.
Whole-tissue ACE2 mRNA expression and recent
scRNA-seq studies reported high ACE2 expression in
cardiac pericytes and cardiomyocytes, epithelial cells of
the oral mucosa, ileum, stomach, colon and rectum,
proximal renal tubules, and endothelial cells14,27,28.
Similar to the lung, coexpression of ACE2 and TMPRSS2
in corneal, intestinal, and nasal epithelial cells is asso-
ciated with activation of innate immune pathways, high-
lighting these cells as having potential roles in initiating
viral infection29. TMPRSS2 expression facilitates SARS-
CoV-2 S protein-mediated entry in human ACE2+ mature
enterocytes in human small intestinal enteroids30. In the
eye, high coexpression of ACE2 and TMPRSS2 has been
observed in mouse cornea and human pterygium cell
lines31, which may explain SARS-CoV-2 detection in the
tears and conjunctival secretions of COVID-19 patients
with conjunctivitis32. Thus, organ systems expressing host
entry factors can explain extrapulmonary symptoms such
as diarrhea and conjunctivitis.
Given the greater risk of mortality in COVID-19
patients with cardiovascular disease, regulation of ACE2
in the cardiovascular system is a mechanism that may be
involved. For instance, upregulated ACE2 expression has
been observed in the myocardium of COVID-19 patients
with heart failure33, and single-nucleus RNA-seq (snRNA-
seq) analysis has revealed higher ACE2 expression in
myocytes from patients with cardiomyopathy than in
healthy controls. Under cardiac stress conditions, ACE2 is
repressed while ACE is induced, with consequent
increased angiotensin II-mediated cardiac hypertrophy
and fibrosis34. This response to cardiac stress in endo-
thelial cells is the result of forkhead box M1 (FOXM1)
promoter binding. In addition, regulation of ACE2 in the
cardiovascular system appears to be cell-specific, as ACE2
was found to be expressed at low levels in cardiac fibro-
blasts but highly expressed in myocytes, macrophages and
endothelial, and smooth muscle cells35.
Postmortem studies have provided direct evidence of
viral RNA in the lungs and pharynx and, to a lesser extent,
in the renal tubules, liver, heart, brain, and blood36.
Similarly, endothelial dysfunction in postmortem lung
and kidney tissue is associated with viral inclusion bodies,
suggesting direct viral infection37. Hence, differential tis-
sue expression of ACE2 and TMPRSS2 might link viral
injury to organ systems and may explain the observed
correlation between high respiratory and plasma viral
loads and severe COVID-19 and mortality38,39. Other
studies, however, have reported no association between
viral load and disease severity40. This is supported by a
systematic meta-analysis of viral load dynamics in
COVID-19 whereby no viable virus was detected beyond
day nine of the disease, despite prolonged SARS-CoV-2
RNA shedding in respiratory and stool samples10. Fur-
thermore, a postmortem study demonstrated disconnect
between SARS-CoV-2 detection and organ inflammation
and dysfunction41. Together, these results suggest that
disease progression and mortality may not be directly
virus dependent but rather driven by aberrant host
immune responses.
Host factor expression associated with COVID-19
risk factors
Male sex has been independently associated with severe
COVID-19 disease at presentation, the need for intensive
care unit admission, and higher case fatality rates42. Dif-
ferential host factor expression may explain the sex dif-
ference in COVID-19 (Fig. 1a, b), though the evidence is
conflicting. A recent meta-analysis of scRNA-seq studies
showed increased overall ACE2 and TMPRSS2 lung
expression in males43; in contrast, others have found no
significant sex difference with regard to ACE2 expres-
sion44,45. Given the relatively low expression of ACE2 and
predominant AT2 cell expression, data for whole tissues
compared to single-cell studies may also mask subtle
differences. It is also noteworthy that while ACE2 is
located on the X chromosome, analysis of GTex data
suggests that ACE2 escapes X chromosome inactivation,
resulting in sex-biased gene expression46. Sex differences
in ACE2 expression may also be due to regulation by
hormone-dependent TFs. In female mice, ACE2 basal
activity in the kidney was repressed by estrogen, sug-
gesting estrogen receptor (ER) response elements at the
ACE2 locus47. In the elderly human male atrial myo-
cardium, ex vivo administration of estrogen induced
ACE2 mRNA through an ERα-dependent mechanism48.
Although these findings support ACE2 control via an ER
response element, differences in the response might vary
by tissue type, sex, age, and pathological state.
DNase-seq has revealed differential shared and tissue-
specific regulatory element activation for the ACE2 and
TMPRSS2 loci49 (Fig. 2a), likely regulated by cell-specific
TF binding at regulatory elements50. ENCODE datasets
show binding of the insulator CCCTC-binding factor
(CTCF) at shared sites for ACE2 and TMPRSS2, whereas
activator protein-1 (AP-1) subunits bind to the tissue-
specific 5′ upstream element of ACE2, suggesting that
variable host factor gene expression may be explained by
differential engagement of regulatory elements and
selective TF binding.
Regulation of TMPRSS2 has primarily been explored in
prostate cancer. In this context, TMPRSS2 is induced by
androgens through a distal androgen receptor (AR)
binding enhancer51, resulting in AR-induced expression
of a TMPRSS2-ERG (ETS-related gene) fusion gene con-
ferring prostate cancer pathogenicity52. Mapping of an AR
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Fig. 2 (See legend on next page.)
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response element to the induction of TMPRSS2 expres-
sion has led to the hypothesis that androgenic phenotypes
are risk factors for COVID-1953. Epidemiological studies
have also suggested androgenic alopecia as a separate risk
profile for COVID-1954. However, AR blockade in mice
did not alter lung TMPRSS2 expression55, suggesting that
lung TMPRSS2 may not be androgen regulated, possibly
through tissue-specific enhancer inaccessibility. As
TMPRSS2 promoters in mammary epithelial cells have
been found to be responsive to estrogens56, the role of
TMPRSS2 in conferring risk in men through sex-specific
expression in relevant tissues remains unclear.
Moreover, sex-biased behavior may contribute to male
predominance of COVID-19. Higher rates of smoking
among men have been hypothesized to contribute to male
predisposition towards the disease57, and active smoking
is implicated as a negative prognostic indicator for
COVID-1924. This would be consistent with increased
ACE2 in the bronchial epithelium58 and small airway
epithelium of chronic smokers45,59. scRNA-seq data
showed dose-dependent upregulation of ACE2 by cigar-
ette smoke in rodent and human lungs, with chronic
smoke exposure triggering an expansion of ACE2+
mucus-secreting goblet cells60.
Age-related dynamics in host factor expression may
similarly explain the greater severity and mortality that
occurs among older patents9,61. Indeed, older age is
associated with higher viral load in oropharyngeal salivary
and respiratory samples62. Lung ACE2 expression has
been shown to increase ~1.2-fold with every 10-year
increase in age44. scRNA-seq of developing mouse lungs
and temporally resolved RNA-in situ hybridization (ISH)
analysis also found an age-related increase in TMPRSS2
expression63. Single-nucleus ATAC-seq (snATAC-seq) in
human AT2 cells demonstrated age-associated changes in
accessible chromatin around TMPRSS2 at sites harboring
sequence motifs for multiple TFs, including forkhead box
A (FOXA), C/EBPα, the proinflammatory factors STAT,
IFN-regulatory factor (IRF), and AP-1, suggesting age-
dependent inflammatory regulation of TMPRSS264. High
ACE2 and TMPRSS2 levels in the elderly may therefore
be associated with increased viral infection, although
altered immune response and physiology may also explain
divergence in severity with age extremes.
Although lower nasal epithelial ACE2 expression
reported in children65 has been suggested to explain the
milder disease observed in this population66, others have
found that pulmonary ACE2 is not reduced in children13.
Furthermore, scRNA-seq and immunohistochemistry of
human respiratory tract tissue indicated no significant
difference in ACE2 localization in those with independent
risk factors for severe COVID-19, such as male sex,
asthma, cardiovascular disease, COPD, diabetes, and
smoking, compared to age-matched healthy controls1,2,13.
This contradictory evidence suggests a complex rela-
tionship between pulmonary ACE2 expression and
COVID-19 as both a viral receptor and protective factor,
implicating other host factors in regulating disease
severity and susceptibility.
Host genetic variants and the spectrum of COVID-
19
Host genetic factors have been implicated in influenza
and zoonotic diseases such as SARS and MERS67,68.
Genetic variants may alter disease through viral infection,
replication or immune function by altering host gene
expression or protein function, leading to heterogeneous
severity.
Genetic variants of ACE2 and TMPRSS2
Human variants of ACE2 could alter the protein inter-
face with the SARS-CoV-2 S protein. Moreover, as ACE2
is located on the X chromosome, hemizygosity for
harmful variants might contribute to poor outcomes in
men with COVID-19. Genomic variant analysis from
Genome Aggregation Database (gnomAD)69 reveals a
very low frequency of non-synonymous ACE2 variants,
including those predicted to be loss-of-function (Fig. 3).
(see figure on previous page)
Fig. 2 ACE2 and TMPRSS2 regulatory elements and tissue-invariant topologically-associated domains. a Human tissue DNase-seq signals for
ACE2 [left] and TMPRSS2 [right] loci. Tissue-specific regulatory elements (red bar) and shared regulatory elements (black bar) are highlighted. Datasets
were obtained from the Encyclopedia of DNA Elements (ENCODE) 2018 data release for Hg3849 and visualized via the UCSC genome browser.
Normalized signal replicate pools are depicted for each tissue type. ENCODE experimental designations are ENCSR747YZZ (small intestine),
ENCSR619JTC (lung), ENCSR955NXV (kidney), ENCSR871OSL (left ventricle) and ENCSR341MVE (brain). b Schematic representation of topologically-
associated domains (TADs) showing boundaries for regulatory elements that control expression of the genes within a TAD. The formation of a TAD is
dependent on insulator elements bound by CCCTC-binding factor (CTCF). Enhancer association with promoters via long-range interactions may act
to regulate expression. Some enhancers harbor SNPs that might alter the expression pattern of genes within a TAD. c Hi-C data for human tissues
depict chromosome conformation into TADs around ACE2 (left) and TMPRSS2 (right). The locations of the respective genes are indicated in black.
Lung, right ventricle, small bowel, and cortex datasets were obtained from Schmitt et al.94. Aorta data were obtained from Leung et al.108. Hi-C
datasets were visualized in HiGlass109 at 20-kb resolution. Datasets are aligned to human genome build Hg38. d Hi-C data for human lung fibroblast
(IMR-90) and human endothelial (HUVEC) cell lines show higher-order chromosome organization as TADs. The genome locations of ACE2 (left) and
TMPRSS2 (right) are indicated in black. Datasets aligned to human genome build Hg18 were obtained from Rao et al.95 and visualized in HiGlass109 at
8-kb resolution.
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Furthermore, no correlation between rare deleterious
ACE2 exonic and splice junction variants with COVID-19
was observed in an Italian population70.
Given the role of ACE2 in cardiovascular disease and
lung disease, including ARDS, ACE2 polymorphisms are
of interest beyond COVID-19. For example, a common
exonic SNP in ACE2, rs2285666 (Fig. 2a), has been
implicated in the risk of cardiovascular disease and type 2
diabetes mellitus, with the rare A allele found at a fre-
quency of 0.2% in European populations and 0.55% in East
Asians70. Two ACE2 intronic SNPs, rs2074192 and
rs2106809, associated with left ventricular hypertension
are expression quantitative trait loci (eQTLs) for ACE2
and may therefore link ACE2 cardiac expression with high
penetrance of alleles, increasing ACE2 expression in East
Asians61. ACE2 variants could therefore be linked to risk
factors for COVID-19, but further clarification within
comorbid subgroups is required.
For TMPRSS2, the frequency of rare deleterious and
common exonic variants speculated to alter protein levels
or activity varies between populations. For common var-
iants, two haplotypes have been identified. One is linked
to an eQTL harboring rs8134378 and mapping to an AR
regulatory element 15 kb upstream of the TMPRSS2 CpG
island70. The second includes the intronic SNP rs2070788
(Fig. 2a), which has been found in small-scale genome-
wide association studies (GWASs) to be linked to an
increased risk of influenza71. Less is known about
TMPRSS2 variants, warranting further investigation.
However, in the first two published GWASs for severe
COVID-19, there was no significant association with
ACE2 or TMPRSS2 variants, suggesting that variants of
these factors do not contribute to COVID-19 severity3,72.
Genetic variants in intracellular RNA sensing and type I
interferon signaling
Based upon the gene mutations implicated in life-
threatening influenza pneumonia, rare but predicted
deleterious mutations have been examined in patients
with severe COVID-1972. Mutations in the genes encod-
ing double-stranded RNA sensor TLR3 and in down-
stream components of type I IFN cell-intrinsic immunity
have been detected, including UNC93B1, which forms a
complex with and is involved in intracellular trafficking of
TLR373 and other downstream components, such as TRIF
and TBK1, a key kinase linking pattern recognition
receptor activation and activation of ISGs. Mutations in
the type I IFN amplification pathway were also found,
including in the genes coding for IRF7 and the cell surface
receptors IFNAR1 and IFNAR2. In addition, common
variants at IFNAR2 were found in a GWAS for severe
COVID-193. Although no rare variants in the JAK/STAT
pathway downstream of IFNAR1/2 have been reported in
severe COVID-19, variants at TYK2 on chromosome 19
were reported in the GWAS of a UK intensive care cohort
of COVID-19 patients with critical respiratory failure3. Of
Fig. 3 Single-nucleotide polymorphism (SNP) allelic frequencies of angiotensin-converting enzyme 2 (ACE2). ACE2 (chromosome X:
15579156–15620271) exon coding transcripts are represented by boxes and corresponding shaded areas. Predicted loss-of-function (pLOF) and
missense variants (top panel) and intron, splice region, 5’ untranslated region (UTR), and 3’UTR variants (bottom panel) are shown. The size of the dot
reflects the minor allele count (range: 1-45,478), with minor allele frequency represented on the y-axis. Data were obtained from gnomAD v2.1.169.
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note, patients with complete TYK2 deficiency are sus-
ceptible to bacterial and viral infection74. The contribu-
tion of genetic variants to reduced IFN signaling in severe
COVID-19 is further supported by observations of
impaired IFN responsiveness in neutrophils from patients
with severe COVID-1975. Nonetheless, the WHO Soli-
darity Trial has shown that treatment of COVID-19
patients with IFN-β1a did not decrease mortality or the
need for mechanical ventilation76.
Some critical COVID-19 patients with mutations in IFN
pathways exhibit reduced serum IFN-α72, though other
studies have reported higher IFN-γ in helper T cells of
patients who died from COVID-1977. IFN-γ is linked to
IL-6 signaling through the IL-6 receptor (IL6R)78, sug-
gesting interplay between IFN and interleukin signaling in
acute inflammation. Genetic variants of IL6R are asso-
ciated with a lower risk of hospitalization following SARS-
CoV-2 infection79, yet these variants were not significant
in the COVID-19 GWASs above. Nevertheless, modula-
tion of the IL6R axis using inhibitors, such as tocilizumab
and sarilumab, was shown in the REMAP-CAP and
EMPACTA trials to reduce the need for mechanical
ventilation and reduce mortality in patients with severe
COVID-1980,81.
In the first published GWAS for severe COVID-19, a
significant cross-replicating locus at 3p21.31 was found in
Italian and Spanish populations82, spanning six genes:
LC6A20, LZTFL1, CCR9, FYCO1, CXCR6, and XCR1
(Fig. 4). The insertion–deletion GA risk variant of
rs11385942 in an intron of LZTFL1 is associated with
reduced CXCR6 but increased SLCA20 expression.
Interestingly, the risk allele was detected frequently in
patients who required mechanical ventilation, and fur-
thermore, the few individuals homozygous for the risk
allele were younger, suggesting an association with
COVID-19 severity. The frequency of risk allele hetero-
zygosity varies between populations, occurring in less
than 0.5% in China and 37.8% in Bangladesh82. Moreover,
a GWAS of the UK intensive care cohort of COVID-19
patients with critical respiratory failure3 replicated the
significance of the chromosome 3 locus.
The genes at the 3p21.31 locus have plausible roles in
COVID-19 and lung injury. SLC6A20 encodes a sodium-
dependent amino transporter that has been shown to
interact with ACE2 in a Xenopus oocyte expression sys-
tem83. CXCR6 is a marker of lung-resident memory CD8+
T cells, producing cytokines in response to stimuli84. Its
ligand, CXCL16, is elevated in the serum of patients with
acute lung injury, and both ligand CXCL16 and CXCR6
receptor genes are upregulated in models of lung injury9.
CXCL16-CXCR6 acts to disrupt epithelial integrity
through downregulation of E-cadherin in lung injury9,
which might represent the fibrosis observed in ARDS.
CCR9, as part of a CCL25-CCR9 chemokine axis, has
been shown to mediate gut-specific recruitment of lung
IFN-γ-producing CCR9+CD4+ T-cells in influenza, con-
tributing to the gut injury observed in viral infection64.
FYCO1, encoding an autophagy adaptor protein, was
found to be upregulated in intensive care patients with
sepsis85.
The second locus uncovered by Ellinghaus et al. maps to
the ABO blood group gene, whereby group A confers a
higher risk of severe COVID-19 and group O demon-
strates a protective effect82. The plausibility of an asso-
ciation is supported by an epidemiological study in a
Chinese population, showing increased COVID-19 risk
with blood group A and reduced risk with blood group
O86. However, the association of ABO blood groups with
COVID-19 severity was not replicated by the GenOMICC
study3. Additional loci associated with COVID-associated
ICU admission include the OAS gene cluster on chro-
mosome 12 and DPP9 on chromosome 193. OAS genes
are activated by IFN and are involved in double-stranded
RNA degradation pathways in the early innate antiviral
response87,88. DPP9 encodes a serine protease implicated
in lung fibrosis89. These pathways may therefore represent
Fig. 4 The 3p21.31 locus harbors significant single-nucleotide variants from the COVID-19 GWAS. The COVID-19 GWAS identified SNPs
mapping to the 3p21.31 locus. The lead SNP from each study (rs11385942 from Ellinghaus et al.82; rs73064425 from Pairo-Castineira et al.3) mapped to
LZTFL1. Images were generated from the UCSC genome browser (hg38, chr3:45,388,000–46,361,000), showing RefSeq genes and Genotype-Tissue
Expression (GTEx) RNA-seq data for selected tissues107.
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therapeutic targets to mitigate progression to critical
respiratory failure in COVID-19.
Mechanisms of genetic variants driving increased disease
risk
Most GWAS disease-risk loci are in noncoding regions
of the genome90. The cataloging of human regulatory
elements on a genome-scale across multiple cell and tis-
sue types has uncovered a correlation between accessible
chromatin, DNA-binding factors and SNPs91. These
large-scale studies implicate altered TF binding as a core
feature of noncoding genetic variants. For example, in
lymphoblastoid cell lines, interindividual variation in NF-
kB binding has been associated with genetic variants and
alterations in gene expression92. Genetic variation could,
therefore, alter responses to stimuli, such as infection,
between individuals and thus influence severity.
To infer phenotypic consequences of genetic variants,
functional assignment of genetic variants to gene regula-
tion is required but remains challenging. Chromatin
structure can be used to aid functional characterization of
variants. Chromatin higher-order structures have been
found to form topologically-associated domains (TADs),
regions of chromatin that show high interaction fre-
quencies separated by boundary regions93 (Fig. 2b). At the
megabase scale, TADs are generally stable between cell
types and tissues94,95. TAD boundaries are marked by
binding sites for CTCF, which impedes cohesin-driven
loop extrusion, the process responsible for TAD forma-
tion. For the most part, enhancers are generally found in
the same TAD as the gene(s) they regulate96. Therefore,
incorporating information on chromatin structure,
including smaller scale accessibility information with
larger scale TADs, may aid in the discovery of associations
between noncoding variants and genes to guide fine-
mapping experiments97 and has allowed functional
refinement of SNPs and eQTLs98.
ACE2 and TMPRSS2 are located within tissue-
conserved TADs (Fig. 2c, d). However, eQTL analysis of
SNPs at the ACE2 locus did not reveal an association with
gene expression in lung tissue99. Within the ACE2 TAD
(hg38 chrX:15,300,000–15,600,000), long-distance inter-
actions were observed between multiple SNPs and other
genes associated with eQTLs in the lung, such as PIR, a
modulator of NF-kB signaling, and CA5B, which is
involved in acid-base metabolism99.
Incorporating open chromatin might also contribute to
the identification of functional genetic variants. By
applying snATAC-seq to healthy human lungs, age-
dependent accessible regions in TMPRSS2-expressing
AT2 cells were found to be enriched for genes associated
with inflammatory signals100. In AT2 cells, age-dependent
accessible chromatin near TMPRSS2 correlated with
sequence variants, including common variants with a
minor allele frequency >1%100. These variants are pre-
dicted to disrupt sequence motifs of DNA-binding factors
and thus alter expression and are associated with GWAS
phenotypes for emphysema, asthma, and bacterial
pneumonia100.
Conclusion
The sequalae following SARS-CoV-2 infection are
highly heterogeneous, from asymptomatic to multiorgan
failure, and host factors are likely variables involved in
COVID-19 severity101. Risk factors for COVID-19 con-
tribute to modified disease risk through changes in
viral–host interactions, most likely through host factor
expression. ACE2 and TMPRSS2 have been identified as
SARS-CoV-2 tropic factors. However, ACE2 was found to
be protective against pulmonary injury through main-
tenance of vascular competence in mouse models of acute
lung injury102. The balance between viral exploitation of
host factors and the role of that factor in COVID-19
pathophysiology is not clear. Furthermore, ACE2 and
TMPRSS2 genetic variants are not convincingly associated
with COVID-19 severity3,82. Other important host factors
involved in viral–host interactions, viral protein proces-
sing, and immune function are more likely to contribute
to severity. The therapeutic effect of glucocorticoids, such
as dexamethasone103 or hydrocortisone104, in decreasing
COVID-19 mortality or the need for organ support
strongly suggests an inflammatory process in severe dis-
ease. IFN pathways are also likely to play key roles in
COVID-19, and their impairment might explain pro-
gression to critical illness. While the WHO Solidarity trial
does not support the use of IFN as a treatment modality76,
questions on the timing and regime remain while high-
lighting a need for alternate targets. Exploring the
expression variation and regulatory control of other host
factors, such as the 3p21.31 locus identified from COVID-
19 GWASs, will aid in our understanding of the disease
spectrum and uncover therapeutic targets3,82. It will also
be important to integrate comorbidities with the genetic
variants implicated in COVID-19 to understand the
contributions of risk factors to COVID-19 severity.
The identification of functional regulatory elements in
health and pathological states is a crucial pursuit, with
many approaches being developed following the mapping
of noncoding genomic regions. We have highlighted a
number of methods that have been employed to identify
regulatory elements, but their use in conglomerate is
likely required, taking a multiomics approach to identify
functional consequences. This is particularly important
for understanding dynamic changes in regulatory control,
for instance, during inflammation. The development of
single-cell methodologies, as an example, has also revo-
lutionised our discovery and understanding of cell types
and heterogeneous RNA expression in complex tissues.
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Nevertheless, functional studies of complex tissues have
been largely limited to model organisms, with question-
able translational potential. The development of human
organoid systems may allow for a more relevant under-
standing of the molecular processes that drive variation in
disease presentation and progression. Combining these
approaches with functional assays for regulatory control
of gene expression by using, for example, high-throughput
CRISPR-based perturbation methods105 or a high-
throughput self-expressing reporter system to identify
functional enhancer elements in cell-specific control106,
would allow dissection of the roles of regulatory elements,
genetic variants or biological pathways in disease pro-
cesses such as viral infection. Such approaches will allow
the identification of variables to allow risk stratification
for public health initiatives, resource allocation for at-risk
groups and the development of novel therapeutics.
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